Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $11.6667.

ACRV has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Acrivon Therapeutics in a report on Monday, March 2nd. Wall Street Zen downgraded shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 1st. Finally, Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st.

Acrivon Therapeutics Price Performance

ACRV stock opened at $1.68 on Monday. The stock has a market cap of $71.90 million, a P/E ratio of -0.84 and a beta of 1.90. Acrivon Therapeutics has a twelve month low of $1.15 and a twelve month high of $3.56. The business’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.80.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). On average, equities research analysts expect that Acrivon Therapeutics will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRV. Focus Partners Wealth bought a new position in shares of Acrivon Therapeutics during the third quarter worth $36,000. Schonfeld Strategic Advisors LLC purchased a new position in Acrivon Therapeutics during the fourth quarter valued at $40,000. Vermillion & White Wealth Management Group LLC purchased a new position in Acrivon Therapeutics during the fourth quarter valued at $44,000. Quadrature Capital Ltd purchased a new position in Acrivon Therapeutics during the fourth quarter valued at $50,000. Finally, Invesco Ltd. purchased a new position in Acrivon Therapeutics during the first quarter valued at $72,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.